MyMD Pharmaceuticals is a provider of rapid diagnostic solutions. Co.'s commercialized product portfolio incorporates the following proprietary platform testing and sample preparation technologies: Particle Immuno-Filtration Assay, an immunoassay method based on the selective filtration of dyed microparticles coated with antigen or antibody; MicroParticle Catalyzed Biosensor, which permits the identification of medical conditions through biomarkers in exhaled breath; and Rapid Blood Cell Separation Technology, which increases the rate at which a test result is obtained as the often-required sample preparation step is abbreviated. The MYMD stock yearly return is shown above.
The yearly return on the MYMD stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2017 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the MYMD annual return calculation with any dividends reinvested as applicable (on ex-dates).
|